Polar Asset Management Partners Inc. Takes $7.74 Million Position in Kenvue Inc. $KVUE

Polar Asset Management Partners Inc. purchased a new stake in Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 405,241 shares of the company’s stock, valued at approximately $7,744,000.

Other hedge funds have also bought and sold shares of the company. Physician Wealth Advisors Inc. grew its position in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Kenvue in the fourth quarter valued at approximately $26,000. Johnson Financial Group Inc. bought a new stake in shares of Kenvue in the second quarter valued at approximately $26,000. MV Capital Management Inc. bought a new stake in shares of Kenvue in the fourth quarter valued at approximately $28,000. Finally, CoreCap Advisors LLC grew its position in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after buying an additional 591 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Down 0.4%

NYSE KVUE opened at $19.34 on Wednesday. The business has a fifty day moving average price of $19.10 and a two-hundred day moving average price of $18.22. The stock has a market capitalization of $37.16 billion, a PE ratio of 22.24, a PEG ratio of 1.39 and a beta of 0.47. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $21.40. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. During the same quarter in the previous year, the business posted $0.29 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be paid a dividend of $0.21 per share. The ex-dividend date of this dividend is Wednesday, August 12th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a yield of 4.3%. Kenvue’s payout ratio is presently 96.55%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on KVUE shares. Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Barclays increased their target price on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. UBS Group dropped their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Finally, Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.